Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002
Medication labelWhy this: Advisory · dailymed-prescription
Buprenorphine and naloxone sublingual tablets are indicated for maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support.
- generic_name
- buprenorphine and naloxone
- product_names
- Buprenorphine and Naloxone
- ndc
- 87441-001, 42858-602, 87441-001-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en